CA3049353C - Chaperonin 60.1 Peptides of Mycobacterium Tuberculosis and Their Uses - Google Patents

Chaperonin 60.1 Peptides of Mycobacterium Tuberculosis and Their Uses

Info

Publication number
CA3049353C
CA3049353C CA3049353A CA3049353A CA3049353C CA 3049353 C CA3049353 C CA 3049353C CA 3049353 A CA3049353 A CA 3049353A CA 3049353 A CA3049353 A CA 3049353A CA 3049353 C CA3049353 C CA 3049353C
Authority
CA
Canada
Prior art keywords
seq
amino acid
hglnvntlsygd
acid sequence
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3049353A
Other languages
English (en)
French (fr)
Other versions
CA3049353A1 (en
Inventor
Andrew Lightfoot
Nicola Cooper
Original Assignee
Revolo Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolo Biotherapeutics Ltd filed Critical Revolo Biotherapeutics Ltd
Publication of CA3049353A1 publication Critical patent/CA3049353A1/en
Application granted granted Critical
Publication of CA3049353C publication Critical patent/CA3049353C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
CA3049353A 2017-01-12 2018-01-11 Chaperonin 60.1 Peptides of Mycobacterium Tuberculosis and Their Uses Active CA3049353C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1700557.0A GB201700557D0 (en) 2017-01-12 2017-01-12 Novel peptides
GB1700557.0 2017-01-12
PCT/GB2018/050072 WO2018130834A1 (en) 2017-01-12 2018-01-11 Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof

Publications (2)

Publication Number Publication Date
CA3049353A1 CA3049353A1 (en) 2018-07-19
CA3049353C true CA3049353C (en) 2024-10-29

Family

ID=58463310

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049353A Active CA3049353C (en) 2017-01-12 2018-01-11 Chaperonin 60.1 Peptides of Mycobacterium Tuberculosis and Their Uses

Country Status (9)

Country Link
US (1) US11098090B2 (enExample)
EP (1) EP3568148B1 (enExample)
JP (3) JP7252895B2 (enExample)
CN (1) CN110381979A (enExample)
AU (1) AU2018208077B2 (enExample)
CA (1) CA3049353C (enExample)
ES (1) ES2970436T3 (enExample)
GB (1) GB201700557D0 (enExample)
WO (1) WO2018130834A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12331088B2 (en) 2017-01-12 2025-06-17 Revolo Biotherapeutics Limited Method for the treatment of a relapsing-remitting condition
GB201700555D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Method for the treatment of a relapsing-remitting condition
US12358957B2 (en) 2017-01-12 2025-07-15 Revolo Biotherapeutics Limited Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides
WO2023223015A1 (en) 2022-05-16 2023-11-23 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating food allergies
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet
WO2024218571A1 (en) * 2023-04-18 2024-10-24 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating eosinophilic esophagitis
WO2025037259A1 (en) 2023-08-15 2025-02-20 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating severe asthma
WO2025255468A2 (en) 2024-06-06 2025-12-11 Miguel Guzman Subcutaneous formulation of a peptide derived from chaperonin 60.1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028122D0 (en) 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
FR2858936A1 (fr) 2003-08-22 2005-02-25 Diatos Potentialisation de l'activation de prodrogues de haut poids moleculaire
WO2008033820A2 (en) 2006-09-11 2008-03-20 The Board Of Trustees Of The University Of Illinois Modifications of cupredoxin derived peptides and methods of use thereof
GB0803369D0 (en) * 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
CA2779730C (en) 2009-11-05 2019-04-30 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
GB201118201D0 (en) 2011-10-21 2011-12-07 Helperby Therapeutics Ltd Novel peptides
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides

Also Published As

Publication number Publication date
US11098090B2 (en) 2021-08-24
AU2018208077A1 (en) 2019-07-25
EP3568148A1 (en) 2019-11-20
AU2018208077B2 (en) 2021-11-11
CA3049353A1 (en) 2018-07-19
WO2018130834A1 (en) 2018-07-19
ES2970436T3 (es) 2024-05-28
JP2020504161A (ja) 2020-02-06
JP2025032107A (ja) 2025-03-11
GB201700557D0 (en) 2017-03-01
EP3568148B1 (en) 2023-11-01
US20200071365A1 (en) 2020-03-05
JP7252895B2 (ja) 2023-04-05
JP2023029902A (ja) 2023-03-07
EP3568148C0 (en) 2023-11-01
CN110381979A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
CA3049353C (en) Chaperonin 60.1 Peptides of Mycobacterium Tuberculosis and Their Uses
US11834478B2 (en) Method for the treatment of a relapsing-remitting condition
JP6199296B2 (ja) 新規ペプチド
US12358957B2 (en) Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
US12331088B2 (en) Method for the treatment of a relapsing-remitting condition
CN112694526B (zh) 一种白细胞介素29突变体蛋白
JPH10259198A (ja) 連結したｔ細胞エピトープとその用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111

EEER Examination request

Effective date: 20230111